MarketPeel
Insider Trading Intelligence
Pricing
…
AB

Arie Belldegrun

URGN
DIRECTOR · UROGEN PHARMA LTD. · CIK 0001296549
FILING MIX · LIFETIME81%/19%
BUYS
42
SELLS
10
TOTAL VALUE
$27.59M
COMPANIES
4
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
1,263,581
AVG SELL PX
—
TRADE KIND
SHOWING 52 / 52
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 4 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Arie Belldegrun, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+0.00%-6.86%-1.60%-5.26%-3.82%—
14d6+0.00%-8.17%-1.25%-6.92%-5.85%—
30d6+33.33%-6.53%-0.11%-6.42%-5.20%—
60d6+0.00%-12.32%+2.50%-14.82%-13.72%—
90d6+33.33%-9.65%+6.16%-15.81%-26.38%—
180d6+33.33%+4.46%+6.44%-1.98%-5.71%—
1y6(2 pending)+0.00%-48.90%+18.82%-67.72%-79.74%—
2y6(2 pending)+0.00%-65.48%+29.52%-95.00%-97.34%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
URGN · 20,000 shares · as of Jun 22, 2026
0102,173204,347306,520408,693202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 42 buys / 10 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
20,000——20,000Jun 22, 2026Jun 23, 2026 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
929,913——929,913Feb 2, 2026Feb 4, 2026 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
263,033——263,033Feb 2, 2026Feb 4, 2026 ↗View →
LBRX
LB PHARMACEUTICALS INC
SALE
30,667——0Sep 12, 2025Sep 16, 2025 ↗View →
LBRX
LB PHARMACEUTICALS INC
SALE
13,302,666——0Sep 12, 2025Sep 16, 2025 ↗View →
LBRX
LB PHARMACEUTICALS INC
PURCHASE
1,262——1,262Sep 12, 2025Sep 16, 2025 ↗View →
LBRX
LB PHARMACEUTICALS INC
PURCHASE
332,566$15.00$4.99M880,214Sep 12, 2025Sep 16, 2025 ↗View →
LBRX
LB PHARMACEUTICALS INC
PURCHASE
767$15.00$11.5K2,029Sep 12, 2025Sep 16, 2025 ↗View →
LBRX
LB PHARMACEUTICALS INC
PURCHASE
547,648——547,648Sep 12, 2025Sep 16, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
20,000——20,000Aug 26, 2025Aug 27, 2025 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
369,957——2,236,816Jan 24, 2025Jan 28, 2025 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,307,927——1,307,927Jan 24, 2025Jan 28, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
10,000——10,000Aug 6, 2024Aug 7, 2024 ↗View →
DNA
GINKGO BIOWORKS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
571,428——571,428Jun 13, 2024Jun 14, 2024 ↗View →
DNA
GINKGO BIOWORKS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
432,900——432,900Jun 13, 2024Jun 14, 2024 ↗View →
DNA
GINKGO BIOWORKS HOLDINGS, INC.
PURCHASE
105,263——194,925Jun 12, 2024Jun 14, 2024 ↗View →
DNA
GINKGO BIOWORKS HOLDINGS, INC.
SALE
105,263——0Jun 12, 2024Jun 14, 2024 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
344,828$2.90$1.00M539,867May 16, 2024May 20, 2024 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
1,724,137$2.90$5.00M1,724,137May 16, 2024May 20, 2024 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
211,973——1,866,859Jan 25, 2024Jan 31, 2024 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
749,398——749,398Jan 25, 2024Jan 31, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
10,000——10,000Sep 7, 2023Sep 8, 2023 ↗View →
DNA
GINKGO BIOWORKS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
139,860——139,860Jun 16, 2023Jun 21, 2023 ↗View →
DNA
GINKGO BIOWORKS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
105,263——105,263Jun 16, 2023Jun 21, 2023 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
994,800——994,800Mar 22, 2023Mar 24, 2023 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,282,976——1,654,886Mar 22, 2023Mar 24, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
160,000——0Sep 14, 2022Sep 16, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
160,000$5.00$800.0K408,693Sep 14, 2022Sep 16, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
3,241$5.00$16.2K248,693Aug 31, 2022Sep 1, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
3,241——0Aug 31, 2022Sep 1, 2022 ↗View →
DNA
GINKGO BIOWORKS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
108,516——108,516Jun 10, 2022Jun 13, 2022 ↗View →
DNA
GINKGO BIOWORKS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
70,921——89,662Jun 10, 2022Jun 13, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
10,000——10,000Jun 8, 2022Jun 10, 2022 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,458,333——1,458,333Mar 23, 2022Mar 23, 2022 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
4,710,121——4,710,121Mar 14, 2022Mar 31, 2022 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
4,710,121——0Mar 14, 2022Mar 31, 2022 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
4,710,120——4,710,120Mar 14, 2022Apr 1, 2022 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
4,710,120——0Mar 14, 2022Apr 1, 2022 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
155,039$12.60$1.95M195,039Jan 12, 2022Jan 14, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
10,000——10,000Jun 7, 2021Jun 8, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
379,066——0May 24, 2021May 24, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
379,066$18.22$6.91M583,034May 24, 2021May 24, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
53,635——203,968Mar 26, 2021Mar 30, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
199,223——199,223Mar 26, 2021Mar 30, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
3,241——0Mar 26, 2021Jun 8, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
3,241$5.00$16.2K245,452Mar 26, 2021Jun 8, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
3,241——0Mar 24, 2021Apr 22, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
3,241$5.00$16.2K245,452Mar 24, 2021Apr 22, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
10,000——10,000Jun 8, 2020Jun 9, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
40,000$47.00$1.88M40,000Jun 4, 2020Jun 4, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
106,382$47.00$5.00M1,798,163Jun 4, 2020Jun 4, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
379,066——379,066Mar 18, 2020Mar 20, 2020 ↗View →
Other insiders · URGN
Loading peer insiders…
About this filer
CIK 0001296549
ROLE
Director
PRIMARY
URGN
COMPANIES
4
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001296549DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback